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Acetylcholinesterase: enzyme that breaks down acetylcholine at synapses.
Cholinergic system: nervous system pathways that use acetylcholine as a
neurotransmitter. This includes cholinergic neurons in the basal forebrain that
project to the cerebral cortex.
COMT (catechol-O-methyltransferase): enzyme that degrades catecholamines,
including dopamine, at synapses.
DAT (dopamine active transporter): membrane-spanning protein that pumps
dopamine from the synapse back into the cell, thereby reducing its synaptic
concentration.
Dementia with Lewy bodies (DLB): form of dementia characterized by the
presence of Lewy bodies (consisting of a-synuclein and ubiquitin proteins),
closely related to Parkinson’s disease with dementia (PDD).
Dopaminergic system: neurons that use dopamine as a neurotransmitter have
cell bodies located in the midbrain. The mesolimbic pathway and mesocortical
pathway originate in the ventral tegmental area to innervate the limbic system
and cerebral cortex, respectively, whereas the nigrostriatal pathway projects
from the substantia nigra to innervate the caudate and putamen.
Glutamate: ionized form of the amino acid glutamic acid; acts as an excitatory
amino acid transmitter.
Heteroreceptors: receptors on axons that are specific for neurotransmitters
released by other cells at axon–axon synapses.
Histaminergic system: neurons that use histamine as a neurotransmitter have
cell bodies in the hypothalamus and project to brain regions including the
cerebral cortex.
NMDA receptor: class of glutamate receptors activated by N-methyl-D-
aspartate.
Noradrenergic system: neurons that use noradrenaline as a neurotransmitter
project from cell bodies in the locus coeruleus in the pons to innervate the
cerebral cortex.
Nucleus accumbens: part of the basal ganglia. Its inputs include dopaminergic
neurons from the ventral tegmental area via the mesolimbic pathway.
Serotonergic system: neurons that use serotonin as a neurotransmitter project
from cell bodies in the brainstem (notably in the raphe nucleus) to the cerebral
cortex.Attempts to improve cognitive function in patients with
brain disorders have become the focus of intensive re-
search efforts. A recent emerging trend is the use of so-
called cognitive enhancers by healthy individuals. Here,
we consider some of the effects – positive and negative –
that current drugs have in neurological conditions and
healthy people. We conclude that, to date, experimental
and clinical studies have demonstrated relatively modest
overall effects, most probably because of substantial
variability in response both across andwithin individuals.
We discuss biological factors thatmight account for such
variability and highlight the need to improve testing
methods and to extend our understanding of how drugs
modulate specific cognitive processes at the systems or
network level.
Uses of cognitive enhancement
In the last decade, pharmacological treatments aimed at
improving cognitive function across a range of brain dis-
orders have been explored and have even become estab-
lished in clinical practice [1]. In developmental conditions
such as attention deficit hyperactivity disorder (ADHD),
drugs acting on the noradrenergic and dopaminergic sys-
tems, such as methylphenidate and atomoxetine, are now
in widespread use [2–4]. For neurodegenerative disorders
such as Alzheimer’s disease and Parkinson’s disease,
acetylcholinesterase inhibitors (AChEIs) and memantine
[an N-methyl-D-aspartate (NMDA) receptor antagonist]
are now standard treatments [5–9].
In chronic mental disorders such as schizophrenia, cog-
nitive deficits are a separable feature from positive (e.g.
hallucinations and delusions) and negative (e.g. blunted
affect, poverty of speech) symptoms, with current antipsy-
chotic treatments having little, if any, impact on cognitive
impairments. A wide range of compounds is therefore being
assessed for cognitive enhancement in this disorder [10].
Similarly, attempts to ameliorate cognitive deficits follow-
ing stroke are being actively explored [1,11–13], although
none have been established.Many such cognitive enhancers
target neuromodulatory systems – cholinergic, dopaminer-
gic, noradrenergic and serotonergic – ascending from brain-
stem nuclei to innervate both cortical and subcortical
systems (Table 1).
Although most of the reported positive effects of such
drugshavebeenmodest inmagnitude overall andarehighly
variable across individuals, they have had an enormousCorresponding author: Husain, M. (m.husain@ion.ucl.ac.uk).
28 1364-6613 2010 Elsevier Ltd. All rights reserved. doi:10.1016/j.tics.201impact, stimulating interest in cognitive enhancement not
only for patients with brain disorders, but also for healthy
individuals.Compounds such asmethylphenidate andmod-
afinil are used by students in pursuit of better grades,
military personnel who need to remain awake for long
missions, elderly individuals afraid of cognitive decline
and even university academics keen to maintain their per-
formance [14–17].
Herewe focus onwhat aspects of cognition are enhanced,
the magnitude of these effects and possible mechanisms
underlying variations in response across individuals. Our
aim is to highlight key common themes across studies of
clinical populations and healthy individuals, using exam-
ples that highlight these principles. Other recent reviews
provide excellent discussions of ethical issues in cognitive
enhancement [18] and illustrate the complexity of physio-
logical, cellular and computational mechanisms underlying
such effects [19–22].Working memory: process whereby information is held in mind for brief periods.
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Table 1. Summary of the effects of some drugs frequently used as cognitive enhancers
Cognitive enhancer Neuromodulatory mechanism Cognitive functions
improved
Known brain systems
most affected
Currently recommended
clinical use
Methylphenidate,
amphetamine
Dopamine and noradrenaline
reuptake inhibitors
Response inhibition,
working memory, attention,
vigilance
Frontoparietal attentional
systems, striatum, default
mode networks
ADHD, wake-promoting
agent
Caffeine Non-selective adenosine
receptor antagonist
Vigilance, working memory,
incidental learning
Frontal lobe attentional
systems
–
Nicotine Nicotinic cholinergic receptor
agonist
Working memory,
episodic memory, attention
Fronto-parietal attentional
systems, medial temporal
lobe, default mode networks
–
Modafinil Unknown, but effects on
dopamine, noradrenaline and
orexin systems proposed
Working memory,
episodic memory, attention
Frontal lobe attentional
systems
Wake-promoting agent
Atomoxetine,
reboxetine
Noradrenaline reuptake
inhibitors
Response inhibition,
working memory, attention
Frontoparietal attentional
systems
ADHD, depression
Donepezil,
galantamine,
rivastigmine (AChEI)
Blocks enzymatic breakdown
of acetylcholine
Episodic memory, attention Frontal lobe attentional
systems
Alzheimer’s disease,
PDD, DLB
Memantine Noncompetitive, low-affinity,
open channel blocker of the
NMDA receptor
Episodic memory, attention Frontal and parietal lobe Alzheimer’s disease
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What exactly do cognitive neuromodulators do? It might be
tempting to assume a selective one-to-one mapping be-
tween a specific neurotransmitter system and a particular
cognitive function. For example, dopamine has been
strongly linked with working memory (WM) and attention
[19], whereas serotonergic drugs have been prominently
associated with affective processes [23,24]. However, sero-
tonergic modulation can also influence WM [25], as can
noradrenaline and acetylcholine. Conversely, dopamine
influences affective processing [26,27]. A simple mapping
between a specific neurotransmitter and a particular cog-
nitive function described at a very general level – such as
WM – therefore seems untenable. However, subtle but
important differences in the precise processes modulated
might provide some discriminating value: for instance,
dopamine has an established role in reinforcement learn-
ing in response to rewards [28,29], whereas serotonin
seems to modulate reinforcement learning for aversive
stimuli [20,23].
To add to the complexity, neurotransmitters act via a
suite of different receptor systems. Thus, dopamine acting
at D1 receptors can have very different – even opposing –
effects to that of its actions at D2 receptors [19,30]; for
serotonin there are 17 different receptor systems. In ad-
dition, dopamine can have very different effects at differ-
ent brain regions, even within different regions of the
human basal ganglia [31]. Its release can also be modu-
lated in a highly specific regional manner by other neuro-
transmitters, such as glutamate within the nucleus
accumbens [32]. Thus, interactions between neuromodu-
latory systems are also a probable mechanism by which
some of their effects are modulated. For instance, dopa-
mine, noradrenaline and acetylcholine release is under
histaminergic H3 heteroreceptor control [33], whereas
noradrenaline and dopamine can interact to modulate
spatial WM neuronal responses in prefrontal cortex in a
synergistic fashion [19,21]. Again, these considerations
suggest that simple conceptualizations linking a specific
neurotransmitter to a single cognitive function are unlike-
ly to be helpful.Finally, there is increasing evidence that several neuro-
transmitters might have different modes of action when
released in a tonic, sustained manner compared to phasic
release [29,34,35]. For instance, baseline firing of noradren-
ergic cells in the locus coeruleus varies with different states
of alertness or arousal. Optimal responses to environmen-
tally important events seem to be linked to phasic firing of
these cells, but this occurs only when tonic levels of activity
are moderate [35]. Thus, alteration of global concentrations
of a neurotransmittermightmodulate the ability to respond
to external events mediated by phasic firing.
How do drugs currently used as enhancers produce their
beneficial effects? Is it through multiple effects on several
different cognitive processes or do they enhance one cogni-
tive mechanism – such as arousal or improved sustained
attention – through which they lead to better performance
across a battery of tests? For studies in clinical popula-
tions, the difficulty is that many standard cognitive test
batteries used in clinical trials are very unlikely to be
sensitive enough to answer questions on the specificity
of cognitive modulation (Box 1).
For example, AChEIs suchas rivastigmineanddonepezil
are now widely used to treat Parkinson’s disease dementia
(PDD) and the related condition of dementia with Lewy
bodies (DLB). Many clinical trials have reported modest
global beneficial effects of such drugs on bedside cognitive
screening tests [5–7]. More detailed assessment using sen-
sitive computerized cognitive tests has revealedwidespread
improvements in thedomains of attention,WMandepisodic
memory [36–38]. However, these positive effects of AChEIs
mightallbemediatedviaa commonprocesssuchaselevated
arousal [39,40]. In fact, the very same issue pertains to the
modulatory effects of AChEIs in healthy subjects [41]. For
example, in young volunteers, donepezil improves episodic
memory, whereas healthy elderly subjects show improve-
ments in verbalmemory [42]. Is it possible that these effects
could be due simply to a generalized improvement in arous-
al?Studiesdemonstrating thatdonepezil attenuatesdecline
in short-termmemory and visual attention induced by sleep
deprivation [43,44] raise the possibility that this might
indeed be the case.29
Box 1. Measurement of cognitive enhancement in clinical trials
In clinical studies of neurodegenerative conditions – such as
Alzheimer’s disease, Parkinson’s disease with dementia (PDD),
dementia with Lewy bodies (DLB) and vascular dementia – the gold
standard outcome measure has become the ADAS-Cog (Alzheimer’s
Disease Assessment Scale) [91]. This is a relatively short battery of
cognitive tests covering memory, orientation, language, visual
construction and limb praxis skills measured on a 70-point scale.
Drugs approved for use in these clinical conditions have demon-
strated efficacy in changing this measure in the context of a
randomized controlled trial (RCT), in which patients are randomly
assigned either to drug or to placebo. Many trials have also revealed
changes in CIBIC-plus (Clinician’s Interview-Based Impression of
Change) [92], ADAS-CGIC (Alzheimer’s Disease Assessment Scale-
Clinical Global Impression of Change) [92] or Neuropsychiatric
Inventory (NPI) scores [93]. These scoring systems attempt to
capture more global function or psychiatric effects of drug interven-
tions.
For example, the CIBIC-plus is a semi-structured instrument that
attempts to evaluate four areas: general, cognitive and behavioural
functions and activities of daily living, based on the clinician’s
observations of the patient at interview, together with information
supplied by a caregiver. By contrast, the NPI evaluates delusions,
hallucinations, dysphoria, anxiety, agitation or aggression, euphoria,
disinhibition, irritability or lability, apathy, aberrant motor activity,
and night-time behaviour disturbances. It also relies on a structured
interview with a caregiver who is familiar with the patient.
The problem with such scoring systems is that they are relatively
crude and subjective. Many of them were developed for Alzheimer’s
disease and might not be as appropriate for other neurodegenerative
conditions or for individuals performing in the normal range, but at
risk of developing Alzheimer’s disease. For example, fluctuations in
attention or vigilance are a prominent feature of PDD and DLB
whereas impairments in speed of information processing are
common in vascular dementia. These aspects of cognition are not
measured well by batteries such as ADAS-Cog.
Such scoring systems also often lack dynamic range and can be
affected by ceiling or floor effects. Alternative measures comprising
computerized batteries have therefore been used [36,94]. These can give
more sensitive cognitive indices and reaction time measures can avoid
saturation effects. However, they might be time-consuming to perform
and require some degree of expertise to administer and interpret.
Similar issues also pertain to treatment studies of developmental
disorders such as ADHD. Here, rating scales are also used as outcome
measures, with trials showing relatively modest effects compared to
placebo [90,95]. In ADHD too, experimental measures using reaction
time indices, for example to assay response inhibition using the STOP
signal reaction time task, might be more sensitive measures of the
efficacy of drug interventions [96,97].
Review Trends in Cognitive Sciences January 2011, Vol. 15, No. 1Similar considerations as for AChEIs also apply to mod-
afinil, which has become a popular drug for cognitive en-
hancement in healthy individuals. Although its precise
mechanism of action remains to be established, modafinil
is used as a wake-promoting agent for the treatment of
narcolepsy, a disorder associated with excessive daytime
somnolence. Analysis of the effects of modafinil in healthy
subjects has revealed improvements in attention, memory
and executive function in sleep-deprived individuals [17].
However, thismight simply bedue to improvedwakefulness
or arousal induced by the drug [17], just as caffeine can
improve performance on a variety of measures, including
vigilance, and on incidental learning and WM tests [45].
However, it is also important to appreciate that ‘arousal’
[()TD$FIG]
(a) (b
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ptake inhibitor reboxetine improved visuomotor control in healthy volunteers and
primary visual cortex (V1). (b) Dynamic causal modelling demonstrated enhanced
ith permission from [50]).
Box 2. Neuroimaging of drug effects
Although a great deal of work has been performed on furthering our
understanding of the actions of several cognitive enhancers at a
cellular level, it is likely that this level of explanation will be
insufficient, on its own, to account for the effects of drugs on
cognitive performance in both healthy humans and those with brain
disorders. Instead, more insight might be obtained from an under-
standing of the modulatory effects of drugs on large-scale brain
networks underlying cognitive skills at the systems level. Early studies
demonstrated how drugs such as AChEIs and methylphenidate might
modulate visual attention and WM via effects on parietal, frontal and
extrastriate occipital regions [47–49].
More recent investigations have focused on the effects of drugs on
functional connectivity across a brain network. For example, rebox-
etine, a noradrenergic reuptake inhibitor, improved performance on a
visuomotor task, an effect that was associated with enhanced
effective connectivity between right hemisphere parietal and frontal
regions, as well as their influences on left hemisphere regions [50].
Such approaches have also been used to examine more challenging
effects, such as that of modafinil on the noradrenergic locus
coeruleus, a very small nucleus located in the pons [98].
A different approach, applied to clinical populations, has been to
examine brain metabolic network deficiencies associated with neuro-
degenerative conditions, such as motor and cognitive deficits in PD,
using fluorodeoxyglucose PET [99]. Researchers have also started to
use this methodology to investigate the effects of treatment at the
network level, raising the possibility of producing a network-level
account of how a drug might modulate function in a particular brain
disorder. Importantly, different neurodegenerative diseases seem to
have characteristically different effects on the resting-state functional
connectivity across brain network nodes, as indexed by fMRI [100].
Review Trends in Cognitive Sciences January 2011, Vol. 15, No. 1work level in brain disorders are also being applied in
patient groups (Box 2). Finally, it is also crucial to appreci-
ate that non-cognitive factors such as alterations in mood,
anxiety, motivation or apathy induced by a drug can have
indirect effects on cognition. Hence, it is useful to control
for these factors if at all possible.
How effective are the benefits?
Amajor issue in assessing cognitive enhancement studies is
the problem of effect size. First, in studies of healthy sub-
jects, there is no universal, standard battery of tests that
has been agreed on, so comparisons across studies are not
easy. It is not possible to compare effect sizes for different
drugs if the tests used differ in the level of difficulty or
method of measurement (e.g. reaction time vs error rate).
Overall, however, the effects of cognitive enhancers such as
methylphenidate, modafinil and AChEIs in healthy individ-
uals seems to be quitemodest according to recent systematic
reviews [17,41]. Second, many experimental investigations
in healthy subjects have used single-dose assessments
aimed primarily at assessing mechanisms rather than
establishing optimal cognitive enhancement. Very few stud-
ies have examined the effects of repeated doses or long-term
effects, which might be far more revealing and representa-
tive of the overall costs and benefits of taking cognitive
enhancers on a regular basis. Third, as we have seen,
although clinical trials in patients often use standardized
bedside batteries, they might be hampered by their insen-
sitivity and limited range of measurement (Box 1).
Nevertheless, even for these relatively crude measures,
studies in clinical populations have revealed significant
effects of long-term drug use that have led to changes in
practice. For example, one of the remarkable changes in the
management of neurological conditions in the last decade
has been the advent of treatment for cognitive deficits in
neurodegenerative conditions, initially in Alzheimer’s dis-
ease with AChEIs [7]. These studies stimulated clinical
trials in other conditions such as PDD and DLB, with two
majorplacebo-controlled studies involvingover650patients
demonstrating significant positive effects of the AChEI
rivastigmine on cognition and neuropsychiatric measures
such as apathy, anxiety and visual hallucinations [5,6].
Although these trials have now led towidespread clinical
use of rivastigmine, it is important to keep the effect size in
perspective. In the larger study, rivastigmine produced onlya mean 2-point improvement on the ADAS-Cog battery
(Box 1), which has a 70-point range [6]. Similar degrees of
change have been observed in Alzheimer’s disease and
vascular dementia trials with AChEIs (Figure 2a).
Of course, effect sizes vary across individual patients.
Indeed40–80% of PDD or DLB patients might not show a
response to treatment on such clinical measures, but other
individuals show a very strong improvement [5,6]. Overall,
therefore, this means that positive effects have been mod-
erate, at best, when results are examined at the group level
– at least using this currently accepted method for mea-
suring cognition in neurodegenerative clinical trials. Sim-
ilar conclusions have been reached in schizophrenia, for
which there is currently no established treatment for
cognitive enhancement [10]. Thus, interindividual vari-
ability might be one potential reason for small overall
effect sizes (see below).
By contrast, a first glance might indicate far more sub-
stantial effect sizes in treatment trials of ADHD, for which
several drugs that target the catecholaminergic system are
used in clinics. For example, a recent studyusing high levels
of the a2 noradrenergic agonist guanfacine demonstrated a
12-point mean improvement compared to placebo on a
rating scale with a range of 54 points (Figure 2b). However,
these effects were based on ratings by parents or caregivers,
and not on cognitive tests. These might be very valid mea-
sures torate thebehavioural effectsofadrug,but thepoint is
thatwhen considering effect size it is crucial to bear inmind
the nature of the assessments. It is also important to ques-
tion whether there might be negative effects of taking a
compound.
The downside of cognitive enhancers
Like all drugs, those used with the aim of enhancing
cognition can have side effects via body systems other than
the brain. Thus, both AChEIs and methylphenidate fre-
quently cause gastrointestinal upset or nausea, sometimes
leading patients to discontinue medication altogether.
These effects have the potential to offset any positive effects
of the drug on overall performance, and also need to be
borne in mind by anyone contemplating use of such drugs
for non-medicinal purposes. More important from a cogni-
tive neuroscience perspective is the ability of some drugs to
impair certain aspects of cognition while simultaneously
enhancing others in the same individual.31
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Figure 2. Effect sizes of cognitive enhancers in clinical studies. (a) Overall change in ADAS-Cog scores over 6 months on an AChE inhibitor in probable vascular dementia
and Alzheimer disease patients (black circles) compared to patients on placebo (white circles) (adapted from with permission from [89]). (b) Improvements in ADHD Rating
Scale IV with guanfacine at different doses versus placebo over 9 weeks in children and adolescents with ADHD (adapted from with permission from [90]).
Review Trends in Cognitive Sciences January 2011, Vol. 15, No. 1Thus, rivastigmine in healthy elderly subjects can
improve learning on a motor task and making associations
between symbols and digits, but canat the same time impair
verbal and visual episodic memory [51]. Similarly, the dopa-
mine agonist bromocriptine can enhance spatial WM while
simultaneously impairing probabilistic reversal learning in
young participants [52]. This finding echoes results in
patients with PD: dopaminergic medication improves their
performance on WM and task-set switching tasks, but
degrades reversal learning [53,54]. It has been hypothesized
that such opposing effects are due to ‘overdosing’ of ventral
striatal areas involved in the latter, but replenishment of
dopamine in dorsal striatal areas required for the former
[53,55]. Thus, doses of dopaminergicmedication sufficient to
ameliorate motor function and some aspects of cognition in
PD have the potential to worsen others.
Indeed, this conclusion might well be applicable to
recent reports that some PD patients on dopaminergic
agonists developed impulsive behaviours such as gam-
bling, compulsive shopping and hypersexuality [56,57].
It has been reported that such behaviour in PD is often
associated with the presence of dyskinesias, involuntary
movements due to excessive dopaminergic stimulation
[58], consistent with the notion that such impulse control
disorders might indeed be associated with ‘overdosing’ of
some basal ganglia regions. Importantly, reducing the dose
of dopaminergic drugs often leads to reductions in impul-
sivity. These findings show that dopamine agonists in PD
can have a spectrum of effects, both beneficial and harmful,
on cognition and behaviour.
Who benefits from cognitive enhancers?
A major theme that has emerged from studies of neurolog-
ical patient groups is that there is a great variability of
response, with many individuals not responding to treat-
ment on (relatively crude) clinical measures, whereas
others show a very strong improvement, for example in
response to AChEIs [5,6]. Thus, although this group of
patients demonstrates a modest average cognitive change
overall, the effect is likely to be diluted by the fact that
many individuals show very little benefit.32The same issue has arisen in investigations in healthy
individuals: some subjects respond, whereas others might
show little or no benefit. As we discuss below, recent
investigations have begun to question whether such differ-
ences in outcome might depend on genotype and/or the
baseline level of cognitive function. These considerations
also raise concerns about what has become the standard
method of performing clinical drug trials. Large-scale ran-
domized controlled trials offer protection from false posi-
tive findings, but they also have the potential to discard the
fact that some subgroups might benefit from a compound,
whereas others might not.
What might be the cause of such variations in response?
Several studies on the effects of dopaminergic drugs onWM
in healthy volunteers support the conclusion that thosewho
benefitmost are low performers, such as thosewith lowWM
capacity or span. Thus, methylphenidate or dopamine re-
ceptor agonists such as bromocriptine improve WM updat-
ing or retrieval in people who were low performers on study
entry, but can actually impair performance in participants
with high baseline WM spans [47,59–62].
One possible explanation for such contradictory effects
might reside in the classic inverted U-shaped relationship
betweencognitive performanceanddopamine receptor (par-
ticularly D1 receptor) stimulation (Figure 3). Such effects
have been known for a long time, with investigations in
experimental animals revealing that both low and exces-
sively high levels of D1 receptor stimulation in the prefron-
tal cortex can impairWM[63–65]. For optimal performance,
a baseline level between these two extremes is required.
However, until recently, direct evidence in favour of this
concept has been lacking in humans. New findings reveal
that dopamine synthesis capacity in the caudate nucleus of
the basal ganglia is lower in individuals with low WM
spans compared to those with high spans [66]. Participants
in this study were also investigated after taking bromo-
criptine or placebo. Ability to update reward predictions on
a reversal learning taskwas improved by bromocriptine far
more in individuals with low baseline dopamine synthesis
capacity in the basal ganglia. Indeed, high-synthesis sub-
jects were actually impaired in their performance [67].
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Figure 3. Drug concentrations modulate cognition across and within individuals. (a) Evidence from animal studies suggests that modulation of a cognitive process, such as
spatial working memory, by a neurotransmitter such as dopamine might be described by an inverted U-shaped function. Too low or too high a concentration of dopamine
in prefrontal cortex might not produce optimal functional effects. If an individual has low baseline concentrations of dopamine, small increases in concentration might help
to improve performance (red circle). However, individuals with a higher baseline concentration of dopamine (green circle) might actually suffer an impairment of function
on introduction of a drug. (b) Two cognitive processes within the same individual might have differential drug sensitivity (compare functions F1 and F2). In this case, this
individual performed nearly optimally on cognitive function F1 but relatively poorly on function F2 (green circles) before drug administration. Administration of the drug led
to an increase in neurotransmitter concentration from baseline levels. At the new drug level (dashed vertical line) performance on function 1 might theoretically decrease,
whereas cognitive function 2 might now be optimized (yellow circles).
Review Trends in Cognitive Sciences January 2011, Vol. 15, No. 1More recently, it was demonstrated using radioligand
positron emission tomography (PET) imaging that individ-
uals with small levels of dopamine release induced by
methylphenidate improved on a reversal learning task
[31]. By contrast, participants with larger dopamine re-
lease in the caudate nucleus were impaired by the drug.
Importantly, the authors also found that the most impul-
sive subjects (as indexed by their score on an impulsivity
scale) were more likely to improve with methylphenidate.
Thus, both baseline trait impulsivity and methylpheni-
date-induced dopamine release affected response to drugs.
The effects of methyphenidate on spatial WM in healthy
subjects are also most prominent in individuals with the
lowest performance [47]. In ADHD it has similarly been
reported that childrenwith the poorest sustained attention
or highest baseline motor activity are most likely to re-
spond to methylphenidate treatment [68]. The effects of
baseline performance might also be evident for cholinergic
modulation: whereas beneficial effects of donepezil on
cognitive function were evident in healthy participants
whose performance declined after sleep deprivation, those
who were not much affected by sleep loss tended to deteri-
orate after donepezil intake [43,44]. Modafinil also seems
to have the most prominent cognitive effects on attention
and WM in subjects who have low baseline performance
[69,70]. Interestingly, recent studies using magnetic reso-
nance spectroscopy suggest that levels of GABA in specific
brain regions predict differences in individual performance
on cognitive tasks [71,72]. Thus, one reason for baseline
performance modulation of response to drugs might be the
baseline level of a neurotransmitter in a critical brain
region or network.
Effects of genotype on response to drugs
Genetic predictors of individual variability in response to
treatments aimed at improving cognitive function would
clearly be beneficial in effective targeting of therapeutic
strategies. These effects might result directly from varia-tions in efficiency of drug targets or indirectly via metabolic
pathways or other risk genes. Several studies have
suggested a role for polymorphisms in the catechol-O-
methyltransferase (COMT) enzyme-coding region on chro-
mosone 22 in WM [73]. COMT degrades catecholamines,
including dopamine, at the synapse. Polymorphisms of the
COMT gene seem to be associatedwith variability in human
WMperformance andassociated brain activity, presumed to
be via its putative influence on cortical dopamine levels [73].
Amphetamine responses might interact with COMT
activity. When performing a test of cognitive flexibility –
the Wisconsin Card Sorting Test – those with the higher-
activity COMT Val-Val genotype improved, whereas those
with the lower-activity Met-Met genotype deteriorated
after a single dose of amphetamine. An inverted-U rela-
tionship between predicted cortical dopamine levels and
performance is consistent with these findings (Figure 3).
Variations in COMTand the dopamine transporter gene
(DAT) are both obvious candidates for modulation of re-
sponse to psychomotor stimulant treatment in a condition
such as ADHD. DAT is a major target of methylphenidate
and amphetamine, and many treatments for ADHD, in-
cluding the noradrenaline transporter inhibitor atomoxe-
tine, are thought to increase cortical dopamine levels [74],
consistent with a role for COMT. An association between
good clinical response to methylphenidate and carriers of
the high-activity Val polymorphism also suggests a role for
cortical dopamine in mediating treatment response
[75,76]. However, the influence of variable number of
tandem repeats in the DAT gene on methylphenidate
response seems to be mixed [77–79].
Apoliprotein E4 (apoE4), an allele of apolipoprotein E,
which is involved in lipoprotein processing in cells,
increases the risk of developing dementia later in life.
Perhaps paradoxically, young healthy carriers of this ge-
notype, who have a higher risk of cognitive decline later in
life, actually show better performance on decision-making
and prospective memory tasks compared to their apoE333
Box 3. Questions for future research
 Can we improve outcome measures used to study the effects of
drugs in clinical populations?
 Is it possible to improve prediction of which healthy individuals or
patients might respond to a particular cognitive-enhancing drug?
 How do different neurotransmitter systems interact to modulate a
particular cognitive function? Animal studies provide evidence of
such interactions but there are few investigations in humans.
 Is there a role for combined treatments for neurological disorders,
targeting different neurotransmitter systems?
Review Trends in Cognitive Sciences January 2011, Vol. 15, No. 1counterparts [80]. Moreover, nicotine – but not dopaminer-
gic drugs – potentiate the advantage in apoE4 carriers,
producing greater cognitive benefits in these individuals
than in apoE3 carriers on these tasks [80]. The reasons for
this are unclear, but the findings suggest that some genetic
variations influence the integrity of specific neurotrans-
mitter systems, limiting the potential to improve function
in response to drugs acting on the same systems.
For the AChEIs, extensive metabolizers of drugs as
defined by gene variations in cytochrome P450 (a family
of degradative enzymes) might show greater response to
donepezil and rivastigmine [81,82]. This has been demon-
strated using theMini Mental State Examination (MMSE),
which is a relatively crudebedside test of cognition; selective
cognitive tasks have not been used to elucidate process-
specific advantages.
Drug effects and behavioural training
One area that is likely to develop in cognitive enhancement
research is investigation of the interaction between drugs
andbehavioural approaches to improve cognition.Therehas
been a great deal of recent interest in the potential for
cognitive training, for example on WM tasks, to improve
performance not only on these paradigms but also to gener-
alize to other tasks in healthy people, as well as those with
brain conditions such as ADHD [83,84]. fMRI studies in
healthy participants have revealed alterations in activity
acrossparietal and frontal regionsduring such training [85].
Intriguingly, radioligand PET imaging demonstrated asso-
ciated changes in dopamine D1 receptor binding in parietal
and frontal areas [86]. Thus it might be possible to visualize
alterations in neurotransmitter systems as a function of
cognitive training using brain imaging.
An important question for future studies will be wheth-
er there can be synergistic effects of behavioural training
and cognitive-enhancing drugs. Such synergism has been
demonstrated for learning of newmaterial and levodopa in
healthy subjects [87].Whether such combined intervention
might also be useful for cognitive deficits in brain disorders
has yet to be explored in detail. However, there is emerging
evidence of such effects. For example, both memantine and
speech therapy improved dysphasia in stroke patients, but
the combination of the two led to enhanced outcomes [88].
Demonstrations of network-level interactions for drug and
cognitive training in this type of context would be an
important way to investigate the mechanisms underlying
such synergistic effects. Taking the effects of genotype,
baseline cognitive performance and the nature of brain
disorder in patients into account is likely to be an impor-
tant factor in understanding such synergies.
Concluding remarks
It would probably be fair to say that we are still in the first
generation of studies to examine the potential for cognitive
enhancement in humans. In both healthy individuals and
many patient groups, the overall effects of drugs generally
seem to be modest. However, there is evidence that there
might bemore significant effects in subgroups, suchas those
whose baseline performance is poorest or individuals with a
particular genotype.Moreover, new drugs aimed at enhanc-
ing the phasic response of neurotransmitter systems, such34as direct nicotinic agonists for the cholinergic system [34],
mightprove tohavegreater effects thanexistingmodulators
that globally increase levels of a neurotransmitter in a tonic
fashion. The neurobiology underpinning the effects of cog-
nitive enhancers and the mechanisms that determine re-
sponsiveness across individuals promise to be the focus of
research in health and brain disorders in the future (Box 3).
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